New prostate cancer test pinpoints disease better than PSA option, study finds

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option.

Using machine learning, a form of artificial intelligence, Swedish researchers analyzed urine samples from more than 2,000 men with prostate cancer, along with a control group.

They determined that the simple, non-invasive urine test was able to detect biomarkers of prostate cancer with a high degree of accuracy — and could also determine the grade (stage) of the disease.